ARCA Submits Genetically Targeted Beta Blocker for FDA Approval
 
The US Food and Drug Administration this week accepted ARCA Biopharma’s new drug application for its lead product candidate, bucindolol, an investigational, genetically targeted beta-blocker and mild vasodilator for chronic heart failure.
 
“If approved by the FDA, bucindolol could become the first genetically targeted cardiovascular therapy,” ARCA said in a statement.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.